Contact

Career
Country websites

Attention

The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

The product related information on the websites covers – unless explicitly stated otherwise – only CE marked products which are marketable in the European Union. Please be aware that not all products and services described on the following website are cleared or available for sale in all countries. Please check the relevant country web site for details.

By clicking the button “Accepted and Confirmed” you assure that you have taken note of this information.

Back to Homepage Accepted and Confirmed

Critical care

Disclaimer

Not all products and services are cleared or available for sale in all EU countries. Check your country web site for details. 

Acute blood purification

Acute blood purification

Offering renal care and beyond

Learn More
Heart and lung support

Heart and lung support

Treating pulmonary and cardiac failure

Learn More
Therapeutic apheresis

Therapeutic apheresis

Removing harmful substances

Learn More

Shaping the future of multi-organ support

The Critical Care division of Fresenius Medical Care provides hospitals and ICUs with a comprehensive portfolio of technologies for the extracorporeal organ support of critically or otherwise severely ill patients.

As human organs are a mutually linked system, Fresenius Medical Care pursues a multi-organ support approach in Critical Care, drawing on its extensive expertise in extracorporeal blood treatment for acute kidney injury. Based on a holistic comprehension of human physiology, our goal is to develop multi-organ therapies and translate them into smart technology solutions.

cc illustration

With our long-standing experience in renal care, our profound therapeutic design competence and the research and development capabilities of a global leader, we are constantly working to develop new treatment options for unmet clinical needs.

Critical conditions of patients caused by e.g. severe trauma or sepsis are often accompanied by organ failure, rendering multiple organ dysfunction syndrome (MODS) as the main cause of morbidity and mortality in patients admitted to intensive care units.1-4

The early support and stabilization of vital organ functions is crucial for a favorable prognosis of patients5-8 and can provide physicians with an environment and the time in which they can concentrate on treating the root cause of the disease.

Also in terms of preventive measures, the support of malfunctioning organs with extracorporeal therapies can be pivotal for coping with cardiovascular and autoimmune diseases, which would eventually lead to life-threatening conditions if left untreated.

Our multi-organ support portfolio encompasses three main areas: Acute blood purification, Heart and lung support and Therapeutic apheresis.

We offer a wide range of technologies for extracorporeal organ support, built into an ecosystem that delivers along the whole lifecycle of therapy delivery, integrating therapy technology with data analytics and patient management. As a full-service partner, our customers benefit from a holistic offering from a single source that embeds into their clinical infrastructure and daily routines.

Our therapy solutions enable state-of-the-art medical outcomes and provide clinicians with the tools required to practice true interdisciplinary care in an ICU, enabling them to treat critically ill patients with trusted solutions.

1 Sakr Y et al. Crit Care 2012; 16: R222

2 Vincent J-L et al. Crit Care Med. 2006; 16:344-353

3 Angus DC et al. Crit Care Med. 2001; 16:1303-1310

4 Caraballo C et al. Yale J Biol Med 2019; 92:629-640

5 Ferreira FL et al. JAMA 2001; 16:1754-1758

6 Russell JA et al. Crit Care Med 2000; 16:3405-3411

7 Levy MM et al. Crit Care Med 2005; 16:2194-2201

8 Evans L et al. Intensive Care Med 2021; 47:1181-1247

Contact
Country websites

All contact information

Social Media

© Fresenius Medical Care AG 2024

Privacy policy

Cookie settings

Imprint